Tango Therapeutics (TNGX) Depreciation & Amortization (CF) (2020 - 2026)

Tango Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $463000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 22.83% year-over-year to $463000.0; the TTM figure through Mar 2026 stood at $2.1 million (down 13.34% YoY), while the FY2025 annual figure was $2.3 million, down 8.72% from the prior year.
• Depreciation & Amortization (CF) was $463000.0 for Q1 2026 at Tango Therapeutics, down from $481000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $632000.0 in Q2 2024 to a low of $300000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $544588.2 across 5 years, with a median of $600000.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) jumped 102.02% in 2022, then retreated 22.83% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $600000.0 in 2022, then climbed by 2.83% to $617000.0 in 2023, then gained by 0.49% to $620000.0 in 2024, then dropped by 22.42% to $481000.0 in 2025, then fell by 3.74% to $463000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $463000.0 (Q1 2026), $481000.0 (Q4 2025), and $600000.0 (Q3 2025), per Business Quant data.